Polyneuropathy
Drug research and approvals for polyneuropathy: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 165 studies of polyneuropathy are recruiting on ClinicalTrials.gov, Health Canada has authorized 25 drug trials for it since 2013, FDA has 9 approved and 5 open orphan designations naming it, and the EU has 6 authorised medicines for it.
- Recruiting worldwide: 165
- Trials authorized in Canada: 25
- FDA orphan approvals: 9
- EU medicines: 6
- Blood Biomarkers for Prognostic Stratification in Guillain-Barré SyndromeNCT07935733 · Not reported · Anahuac University · starts Dec 1, 2027
- Multimodal Characterization of Movement Trajectories in Chronic Inflammatory Demyelinating PolyneuropathyNCT07882797 · Not reported · Heinrich-Heine University, Duesseldorf · starts Oct 23, 2026
- Comparative Study of Combination Treatment of Bionerv E+ Versus Vitamin B Complex in Treatment of Diabetic…NCT07877948 · Not applicable · BREGO Life Sciences · starts Jul 22, 2025
- Rare Disease Registry Database for Movement Disorders in Southern Anhui ProvinceNCT07838883 · Not reported · First Affiliated Hospital of Wannan Medical College · starts Sep 30, 2026
- Auricular Vagus Nerve Stimulation Mechanisms for HIV-Associated Peripheral NeuropathyNCT07822932 · Not applicable · University of Miami · starts Nov 1, 2026
- TreatHSP Platform: Adaptive Natural History Platform for Ataxias, HSPs, and Spastic AtaxiasNCT07798674 · Not reported · Heidelberg University · starts Jul 16, 2024
- Postoperative Circulating Tumor DNA Monitoring in Stage I-III Driver-Mutant Colon AdenocarcinomaNCT07795528 · Not reported · Ruijin Hospital · starts Aug 14, 2026
- A Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated Sensorimotor…NCT07760818 · Phase 2 · argenx · starts Oct 9, 2026
- A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid TumorsNCT07749586 · Phase 1 / Phase 2 · Arvinas Inc. · starts Jul 29, 2026
How its trials ended
272 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 58 whose ending is known, 47% met their primary endpoint, 7% missed it and 47% stopped early.
- Completed, result not reported10137%
- Ongoing7427%
- Status unknown3914%
- Met its primary endpoint2710%
- Stopped: other or unclear207%
- Missed its primary endpoint41%
- Stopped: enrollment or feasibility31%
- Stopped: lack of efficacy21%
- Stopped: sponsor or business decision21%
| May 29, 2026 | A phase 3, randomized, double-blind, multicenter, placebo-controlled study to evaluate efficacy and safety of inebilizumab in participants with chronic…Uplizna (inebilizumab) | Amgen | Pending |
| Oct 28, 2025 | A phase 3, randomized, double-blinded, placebo-controlled study evaluating the efficacy and safety of empasiprubart iv in adults with chronic inflammatory…Empasiprubart (ARGX-117) | argenx US | Pending |
| Aug 8, 2025 | Phase 3, randomized, double-blinded, double-dummy study evaluating the efficacy and safety of intravenous empasiprubart versus intravenous immunoglobulin in…Empasiprubart (ARGX-117) / Octagam | argenx US | Ongoing |
| May 8, 2025 | A phase 2, open-label study to evaluate the safety, tolerability, and efficacy of intravenous NVG-2089 in participants with chronic inflammatory demyelinating…NVG-2089 | Nuvig Therapeutics, Inc. | Closed |
| Mar 7, 2025 | A phase 2, open-label, proof-of-concept study to investigate the efficacy, safety and tolerability of TAK-411 in adult subjects with chronic inflammatory…TAK-411 | Takeda Pharmaceuticals USA | Ongoing |
| Feb 14, 2025 | Long-term extension study to evaluate the safety and efficacy of riliprubart (SAR445088) in participants with chronic inflammatory demyelinating polyneuropathy…Riliprubart (SAR445088) | Sanofi-Aventis Canada Inc | Pending |
| Aug 16, 2024 | A phase 2, randomized, double-blind, placebo-controlled, dose-finding study evaluating LY3848575 in chronic neuropathic pain associated with distal sensory…LY3848575 | Eli Lilly | Ongoing |
| Jun 13, 2024 | A phase 3, randomized, double-blind, study evaluating efficacy and safety of riliprubart versus intravenous immunoglobulin (IVIG) in participants with chronic…Riliprubart (SAR445088) | Sanofi-Aventis Canada Inc | Ongoing |
| Apr 26, 2024 | A phase 3, double-blind, placebo-controlled study evaluating efficacy and safety of riliprubart in participants with refractory chronic inflammatory…Riliprubart (SAR445088) | Sanofi-Aventis Canada Inc | Ongoing |
| Jun 9, 2023 | A phase 2b, multi-center, randomized, quadruple-blind, placebo-controlled study of batoclimab treatment in adult participants with active chronic inflammatory…Batoclimab (IMVT-1401) | Immunovant Sciences GmbH | Closed |
| Apr 10, 2025 | Vyvgart HytruloTreatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP) | argenx BV | Approved |
| Jun 21, 2024 | Vyvgart HytruloTreatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP) | argenx BV | Approved |
| Jan 12, 2024 | HyQviaTreatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability… | Takeda Development Center Americas, Inc. | Approved |
| Dec 21, 2023 | WainuaTreatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults | Ionis Pharmaceuticals, Inc. | Approved |
| Jun 13, 2022 | AmvuttraTreatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults | Alnylam Pharmaceuticals, Inc. | Approved |
| Oct 5, 2018 | Tegsedi™TEGSEDI® is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. | Akcea Therapeutics, Inc. | Approved |
| Aug 10, 2018 | OnpattroONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. | Alnylam Pharmaceuticals, Inc. | Approved |
| Mar 15, 2018 | HizentraIndicated for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to… | CSL Behring | Approved |
| Sep 12, 2008 | Gamunex-CTreatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) to improve neuromuscular disability and impairment and for… | Grifols Therapeutics, Inc. | Approved |
| Mar 20, 2024 | PrednisoneTreatment of Chronic Inflammatory Demyelinating Polyneuropathy | Sarcomed AB | Designated |
| Oct 14, 2021 | NipocalimabTreatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in adult patients | Janssen Research & Development, LLC | Designated |
| Jul 21, 2021 | Anti-C1s Humanized IgG4 Monoclonal AntibodyTreatment of chronic inflammatory demyelinating polyneuropathy | Sanofi Genzyme | Designated |
| Feb 14, 2018 | Recombinant humanized IgG4 monoclonal antibody against…Treatment of chronic inflammatory demyelinating polyradiculoneuropathy/polyneuropathy (CIDP) | GeNeuro S.A. | Designated |
| Jul 14, 2015 | Recombinant multimerized human IgG1 FcTreatment of chronic inflammatory demyelinating polyneuropathy (CIDP). | Gliknik Inc. | Designated |
| Jul 17, 2025 | AttrogyDiflunisal | Purpose Pharma International AB | EMA ↗ |
| Mar 6, 2025 | WainzuaEplontersen | AstraZeneca AB | EMA ↗ |
| Sep 15, 2022 | AmvuttraVutrisiran · orphan | Alnylam Netherlands B.V. | EMA ↗ |
| Aug 27, 2018 | OnpattroPatisiran · orphan | Alnylam Netherlands B.V. | EMA ↗ |
| Jul 6, 2018 | TegsediInotersen · orphan | Akcea Therapeutics Ireland Limited | EMA ↗ |
| Nov 16, 2011 | VyndaqelTafamidis · orphan | Pfizer Europe MA EEIG | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA